Company - DYSIS Medical

Company

DYSIS Medical is a forward-looking medical technology company that combines innovative computer-aided cervical mapping technology with advanced colposcope design to help healthcare professionals increase detection of cervical lesions and direct the patient journey with greater assurance.

    Board of Directors

    Ken Reali

    Ken is currently the CEO of Bioventus after being appointed to the role in April of 2020. Prior to that, Ken served as President and CEO of Clinical Innovations, a medical device company focused in woman’s healthcare, from June 2015 until its successful sale to Laborie in early  2020. During his twenty-nine-year medical device career, he has gained significant experience in product development, global marketing, business development, commercialization and sales of medical devices. He has a strong background in ethics and compliance, market analysis, reimbursement strategy, regulatory and clinical affairs, new product development, sales force optimization and domestic and international product commercialization.

    Mette Kirstine Agger

    Mette is the Managing Partner at The Lundbeck Foundation. Mette has extensive international experience in biotech / life sciences, more specifically business development and licensing, administration and financing. Mette has been appointed to several board positions at both private and public companies. She has previously co-founded and been CEO of 7TM Pharma A / S. Prior to founding 7TM Pharma, Mette was part of the management of NeuroSearch A / S with responsibility for business development and licenses. She started her career as a patent agent and over the years has helped found several biotech companies. Mette is a biologist from the University of Copenhagen and has an MBA from Henley Business School.

    John Pedersen

    John Pedersen joined DYSIS Medical as Chairman of the Board in December 2019.  Prior to joining the Board of Directors, John was CEO at Augmenix, Inc., which in was acquired by Boston Scientific Corp. in late 2018.  Previous to Augmenix, he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, John was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.  John earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University.

    Casper Breum

    Casper Breum was previously CEO of ilochip A/S, a venture backed company focused on development of diagnostic biochips. Before this he held different positions at H.Lundbeck A/S most recently in corporate business development and strategy where he gained broad international experience. He was also a member of the Board of Directors of the Lundbeck Foundation and Lundbeckfond Invest as an employee representative. Prior to his work at H.Lundbeck, Casper worked for Novo Nordisk A/S and Niels Clauson-Kaas A/S. Casper has an MSc in organic chemistry and an MBA.

    Darin Hammers

    Chief Executive Officer

    Darin Hammers has served as Chief Executive Officer of the Company since September 2018. Mr. Hammers’ experience includes over 25 years of increasing leadership roles in Gynecology and Urology. Prior to joining DYSIS, he served as the President and CEO of Cogentix Medical which was acquired by Laborie in April of 2018.  He joined Cogentix’s predecessor company Uroplasty as Vice President of Global Sales in January 2013 and was promoted to Chief Operating Officer prior to being named interim President and CEO in May 2016, and President and CEO in July 2016. Prior to joining Uroplasty, Mr. Hammers was Vice President of Sales for Bard Medical Division of C.R. Bard based in Covington, GA, focused on Urology care products. Prior to that, Mr. Hammers spent more than 12 years with Boston Scientific in various sales leadership positions in the Urology/Gynecology areas.

    Leadership Team

    Yelena Tropsha

    VP of Clinical, Regulatory and Quality

    Yelena joined DYSIS Medical in July 2021. She brings with her over 25 years of experience in global development of a wide range of medical devices. Most recently she served as the VP of Commercial Access at Neuronetics where she oversaw Clinical, Regulatory, Medical Affairs, Compliance, and Medical Education. Prior to joining Neuronetics, Yelena spent 11 years at Coloplast leading Clinical, Regulatory, and Product Development functions in Urogynecology business. Prior to Coloplast, Yelena held technical leadership positions at Becton Dickinson and Medtronic responsible for technology and product development programs in a number of areas including neuromodulation and arrested heart surgery. Yelena holds an MS in Chemistry and a PhD in Polymer Science from Moscow State University in Russia.

    Brent Palmisano

    Senior VP Commercial Operations - Global

    Brent joined DYSIS Medical in March of 2019 as Senior Vice President of Sales and Marketing managing the global commercial organization. Brent previously spent 15 years at Boston Scientific where he held multiple commercial positions with increasing responsibilities. Most recently, Brent was Area Vice President of Boston Scientific’s National Accounts team. Brent also served as the Director of Marketing and Commercial Integration where he oversaw the commercial development of over 25 devices during his time in marketing. Prior to Boston Scientific Brent spent 7 years at Black and Decker in various sales and marketing positions.

    David Inman

    Chief Financial Officer

    Dave joined the DYSIS Medical team in March 2020.  Prior to DYSIS, Dave was the VP of Finance and Accounting at Augmenix, Inc., which was sold to Boston Scientific at the end of 2018; Dave stayed at Boston Scientific until early 2020 as VP of Finance to help guide the successful transition and integration of the acquisition.  Prior to Augmenix, Dave was with Haemonetics Corporation as head of Global Financial Planning & Analysis, and previously had held Finance, Marketing, New Business Development, and Strategic Planning roles at Boston Scientific Corporation and Staples, Inc.  Dave earned a BA in Economics from the University of Pennsylvania, and an MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.

    Alastair Atkinson

    Chief Operating Officer

    Alastair has over 25 years of Product Marketing, Development, Manufacturing and Sales experience within both corporate and start-up environments. He joined DYSIS Medical from Optos plc where he served as the European General Manager, Global Product Director and was a member of the Senior Management team that floated the company on the main London market in 2006. Prior to joining Optos Mr Atkinson had an 18 year career with Hewlett Packard holding a number of national and international positions. He has a BSc from Reading University, an MSc from Bristol University and completed the Advanced Management Program at INSEAD.

    Darin Hammers

    Chief Executive Officer

    Darin Hammers has served as Chief Executive Officer of the Company since September 2018. Mr. Hammers’ experience includes over 25 years of increasing leadership roles in Gynecology and Urology. Prior to joining DYSIS, he served as the President and CEO of Cogentix Medical which was acquired by Laborie in April of 2018.  He joined Cogentix’s predecessor company Uroplasty as Vice President of Global Sales in January 2013 and was promoted to Chief Operating Officer prior to being named interim President and CEO in May 2016, and President and CEO in July 2016. Prior to joining Uroplasty, Mr. Hammers was Vice President of Sales for Bard Medical Division of C.R. Bard based in Covington, GA, focused on Urology care products. Prior to that, Mr. Hammers spent more than 12 years with Boston Scientific in various sales leadership positions in the Urology/Gynecology areas.